Kornimate/medical-research-clean huggingface dataset:
use of maytenus ilicifolia in the treatment of dyspepsia

Conditions: Dyspepsia

Summary: this study aims to evaluate the therapeutic effect of the infusion of maytenus ilicifolia mart. ex reiss leaves, used for 8 weeks, on patients with dyspepsia. primary endpoint is soda score, secondary endpoint is endoscopic classification (sydney).


Eligibility criteria:
inclusion criteria: * age \> 18 years * being literate * diagnosis of dyspepsia * initial soda score \> or = 25 exclusion criteria: * pregnancy * lactation * allergy to maytenus species * fail to use the drug for 3 uninterrupted weeks * new onset serious adverse events, attributable to the drug * patient's request

Keywords: endoscopy herbal medicine phytotherapy
xeloda plus paclitaxel in gastric cancer with liver metastasis

Conditions: Gastric Cancer

Summary: to investigate the efficacy of capecitabine combined with paclitaxel as neoadjuvant chemotherapy for gastric cancer with liver metastasis only

patients with advanced or metastatic gastric cancer have a poor prognosis. the optimal treatment of gastric cancer with liver metastases without other distant metastases remains a matter for debate and there are few prospective clinical trials to explore this area. the aim of this prospective phase ii study is to evaluate the optimal treatment of gastric cancer with liver metastases. in preclinical xenograft models, capecitabine was highly active against several tumors, including breast, colorectal, gastric, and cervical tumors, and against both 5-fu-sensitive and 5-fu-resistant tumors. intermittent capecitabine (1250 mg/m2 daily dose for 14 days, followed by a 7-day rest period) was shown to be active as a single agent in previously untreated agc patients, with a response rate of 28.2% in 39 patients. the combination of capecitabine with other drugs, such as cisplatin, oxaliplatin, epirubicin, and docetaxel, had an objective response rate of 40-68% as first-line treatment in patients with agc. in human colon cancer xenograft model, thymidine phosphorylase is upregulated and synergy between paclitaxel and capecitabine has been observed. the activity of capecitabine in patients with breast cancer refractory to paclitaxel and anthracyclines suggests that the combination of capecitabine and paclitaxel may be effective in treating patients with advanced breast cancer. doses recommended are capecitabine 1650 mg/m2 per day orally for 14 days and paclitaxel 175 mg/m2 i.v. every 3 weeks. in a phase ii trial with 45 patients involved, 2 patients showed complete response and 20 showed partial response making the overall response rate 48.9% (95%ci:30.3-63.5%). there was no neutropaenic fever or treatment-related deaths. that study demonstrated that paclitaxel and capecitabine combination chemotherapy was active and highly tolerable. the rationale of this study was to find out if outcome could be improved after neoadjuvant chemotherapy with paclitaxel and capecitabine with or without local treatment for patients without other distant metastasis than liver metastasis.

Eligibility criteria:
inclusion criteria: 1. ambulatory males or females, aged no less than 18 years. 2. ecog performance status: 0-1. 3. histologically confirmed gastric adeno-carcinoma. 4. radiologically confirmed liver metastasis without other distant metastasis. 5. no serious concomitant medical illnesses 6. life expectancy more than 3 months 7. be willing and able to comply with the protocol for the duration of the study 8. no prior treatment for metastatic disease 9. give signed informed consent exclusion criteria: 1. not fit for the inclusion criteria 2. not able to comply with the protocol 3. with high risks which may compromise the benefit of proposed regimen 4. active (significant or uncontrolled) gastrointestinal bleeding

Keywords: gastric cancer with liver metastasis
effect of specific mode electroacupuncture stimulation combined with ngf on dysphagia after ischaemic stroke: a pilot randomized controlled trial

Conditions: Ischemic Stroke; Dysphagia

Summary: ischemic stroke is a common clinical disease, often accompanied by dysphagia. at present, clinical treatment for patients with dysphagia after ischemic stroke is limited. the emergence of ngf has surprised the field of neurorehabilitation, but the clinical effect is not satisfactory. the main problem is that ngf is a macromolecular material with a molecular weight of 13.4 kd, which is difficult to penetrate the blood brain barrier. a large number of previous studies in our team have found that electroacupuncture with specific stimulation mode can open the blood brain barrier and induce ngf into the brain. therefore, the purpose of this study is to investigate the effect of specific mode electroacupuncture stimulation combined with ngf treatment on patients with dysphagia after ischemic stroke and to explore the mechanism of this combination therapy to improve brain function, which creates a new method and theoretical basis for nerve rehabilitation of integrated traditional chinese and western medicine.


Eligibility criteria:
inclusion criteria: 1. patients with first-ever ischemic stroke confirmed by computed tomography (ct) and/or magnetic resonance imaging (mri); 2. onset time ranged from 15 days to 180 days; 3. aged 18 to 80 years old, male or female; 4. dysphagia confirmed by a videofluoroscopic swallowing study (vfss); 5. patients who are able to accept and comply with acupuncture, electroacupuncture treatment, gluteal intramuscular injection, and have good compliance; 6. have provided signed consent and exhibit willingness to participate in the trial. 7. women who are lactating, pregnant or intending to get pregnant; exclusion criteria: 1. patients with dysphagia before ischemic stroke onset or dysphagia not caused by ischemic stroke; 2. patients with severe cognitive impairment; 3. patients with severe cardiac, hepatic, and renal dysfunction, as well as severe coagulation abnormalities; 4. patients with other abnormal test results who are deemed unsuitable to participate in this study by the investigator. 5. multiple occurrences of stroke, or a history of craniocerebral surgery, or cerebral infarction caused by trauma or brain tumors. 6. patients with severe neurological deficits prior to ischemic stroke, such as visual and auditory impairments, aphasia, agnosia, severe hemiplegia, and other conditions. 7. women who are lactating, pregnant or intending to get pregnant; 8. patients with a history of needle fainting or with skin infections at the acupuncture site. 9. cardiac pacemaker carrier; 10. patients allergic to ngf; 11. the inability to undergo vfss; 12. patients with a medication history that may alter cortical excitability within the past 2 months. 13. patients who are currently participating in other clinical trials or have participated in clinical trials that ended within the last 3 months.
clinical outcomes of pregnant individuals with epilepsy - prospective study

Conditions: Epilepsy

Summary: the aim of this study is to investigate the pregnancy, delivery, neonatal, and epilepsy outcomes in individuals with epilepsy undergoing pregnancy at the maternal and infant health programs at the university health network - sinai health and followed for epilepsy at the toronto western hospital epilepsy clinic. in particular, we are interested in the association between following recommended epilepsy management guidelines for pregnant individuals with epilepsy and those aforementioned outcomes.


Eligibility criteria:
inclusion criteria: 1. wwe seen at the toronto western hospital epilepsy clinic since june 1st 2022. 2. pregnant at any point between june 1st 2022 and june 1st 2024 (period of enrolment). 3. diagnosed with epilepsy as per the international league against epilepsy (ilae) 2014 definition of epilepsy. exclusion criteria: * none

Keywords: pregnancy neonatal obstetrical anti-seizure medication
longevity, functional status and quality of life of the compress® compliant pre-stress system

Conditions: Compress Compliant Pre-Stress System; Malignant Bone Tumor

Summary: in the treatment of malignant bone tumors, it may be necessary to remove large areas of the femur. to replace these large parts of missing bone, a prosthesis can be used. one innovative technology developed by biomet is the compress® compliant pre-stress system (cps; zimmer-biomet, warsaw, usa). this fixation device uses compression, via a short traction bar, to stimulate osteointegration at the bone-prosthetic interface, promote hypertrophy of the loaded bone, and avoid stress bypass of the host bone around a stiff intramedullary stem. young patients cured of tumors have a long life expectancy and a compelling need for prosthetic fixation that is equally durable. good bone fixation is a prerequisite for implant longevity. although the initial results are encouraging, there is a need for additional mid- to long-term survival data from larger patient series showing longevity of the system, as well as reporting of functional outcome. furthermore, to the best of our knowledge, no study examining the survival of the device using prospective data already exists. in addition, no studies were found examining the quality of life of the patients with the cps system.

in the treatment of malignant bone tumors, it may be necessary to remove large areas of the femur. to replace these large parts of missing bone, a prosthesis can be used. one innovative technology developed by biomet is the compress® compliant pre-stress system (cps; zimmer-biomet, warsaw, usa). this fixation device uses compression, via a short traction bar, to stimulate osteointegration at the bone-prosthetic interface, promote hypertrophy of the loaded bone, and avoid stress bypass of the host bone around a stiff intramedullary stem. young patients cured of tumors have a long life expectancy and a compelling need for prosthetic fixation that is equally durable. good bone fixation is a prerequisite for implant longevity. since 1999, the cps has been routinely placed on the orthopedics - uz leuven service and, as a result, more than 100 patients have been treated in this way. however, there are only few studies reporting on long-term performance of this system. in addition, limited data reporting functional outcome were found. although the initial results are encouraging, there is a need for additional mid- to long-term survival data from larger patient series showing longevity of the system, as well as reporting of functional outcome. furthermore, to the best of our knowledge, no study examining the survival of the device using prospective data already exists. in addition, no studies were found examining the quality of life of the patients with the cps system.

Eligibility criteria:
inclusion criteria: * patients are/will be operated from 26/08/1999 onwards in uz leuven * implantation of the compress compliant pre-stress device * informed consent obtained * patients are able to complete the questionnaires * age: minimum 7 years old exclusion criteria: * n/a
a study using human papillomavirus (hpv) dna testing to detect hpv-related oropharyngeal cancer (opc)

Conditions: Oropharyngeal Cancer; HPV-Related Carcinoma; HPV Positive Oropharyngeal Squamous Cell Carcinoma

Summary: the researchers think that a blood test (navdx®) may be able to identify cancer early by looking for circulating dna from human papillomavirus/hpv. circulating dna are small pieces of genes that are released into the bloodstream. the purpose of this study is to find out whether using this blood test to test for hpv dna will help detect hpv-related oropharyngeal cancer/opc.


Eligibility criteria:
inclusion criteria: * ages 45 and older * self-reported history of four or more lifetime sexual partners * self-reported history of one or more lifetime oral sexual partner * no previous history of diagnosed hpv-related head and neck cancer exclusion criteria: * history of diagnosed hpv-related opc * less than three sexual partners in lifetime * no history of oral sex performed * younger than age 45

Keywords: hpv-related oropharyngeal cancer human papillomavirus oropharyngeal cancer hpv-related carcinoma hpv positive oropharyngeal squamous cell carcinoma cell free human papillomavirus deoxyribonucleic acid cf hpv dna 22-234 memorial sloan kettering cancer center
evaluation of nerve regeneration after nerve transsection using (diffusion-tensor magnetic resonance imaging) dti mr imaging

Conditions: Nerve Degeneration

Summary: to prospectively evaluate the nerve regeneration after traumatic nerve transsection using diffusion tensor magnetic resonance imaging (dti mr imaging).


Eligibility criteria:
inclusion criteria: * patients with traumatic nerve transsection and nerve repair. exclusion criteria: * contraindication for mri; * pregnancy;

Keywords: nerve transsection
the efficacy of a self-fixating mesh in unilateral open inguinal hernia repair

Conditions: Primary Inguinal Hernia; Unilateral Hernia; Open Surgery

Summary: this study's objective is to assess the efficacy of a self-fixating mesh in the surgical repair of unilateral inguinal hernia, which is becoming the new standard of care in open surgical repair of inguinal hernia. the study design is interventional, enrolling 300 patients above 18 years of age, admitted for elective repair in the surgical department of rambam medical health care campus, an academic medical center. the study will assess several outcomes including post-surgical pain, recurrence, quality of life and post surgical complications (e.g. wound infection, the formation of hematoma or seroma, etc).

this study's objective is to assess the efficacy of a self-fixating mesh in the surgical repair of unilateral inguinal hernia, which is becoming the new standard of care in open surgical repair of inguinal hernia. the study design is interventional, enrolling 300 patients above 18 years of age, admitted for elective repair in the surgical department of rambam medical health care campus, an academic medical center. the study will assess several outcomes including post-surgical pain, recurrence, quality of life and post surgical complications (e.g. wound infection, the formation of hematoma or seroma, etc). the data will be compared to the literature and will be statistically analysed. the follow-up for each patient will be two years.

Eligibility criteria:
inclusion criteria: * all patients undergoing primary unilateral open inguinal hernia repair . * patients undergoing elective surgery. * above the age of 18 years old exclusion criteria: * patients having repeated inguinal hernia. * patients having bilateral hernia. * patients undergoing laparoscopic surgery. * patients undergoing non-elective surgery.
evaluate the benefit of an individualised treatment plan (vitalcare) vs soc in osa patients treated with cpap/apap

Conditions: Obstructive Sleep Apnoea Syndrome (OSAS)

Summary: according to a stratification procedure, the objective of a personalised care plan (vitalcare) is to identify points for improvement since the early stage of the patient's pathway of cpap/apap treatment and to adjust patient follow-up .

it is a prospective, exploratory, randomised, multi-centre, open, controlled study with a 1:1 ratio of two parallel groups, with obstructive sleep apnoea patients starting cpap/apap therapy, and receiving by the homecare provider, either an individualised treatment plan (vitalcare) or national standard of care. this study will be conducted in 5 hospital centres in portugal.. during a regular medical consultation, eligible patients who have signed their informed consent will be randomised by their investigator. two study groups will be set up: 1. standard of care group 2. vitalcare group two medical visits in the hospital centres will be scheduled in the context of the study for all participating patients: 1. a screening/inclusion visit before cpap/apap initiation at home; 2. an end-of-study visit planned at 12 months (± 1 month) after cpap/apap initiation at home. all visits done in the hospital centres at the discretion of the investigators between patient's screening/inclusion visit and end-of-study visit will be recorded in the ecrf with the reason for the visit and change in cpap/apap prescription, if applicable the primary objective of this study is to evaluate adherence to cpap/apap treatment at 3 months in patients with individualised treatment plan (vitalcare) compared to patients with standard of care

Eligibility criteria:
inclusion criteria: * patient diagnosed with obstructive sleep apnoea syndrome (osas) who is newly prescribed cpap or apap therapy at inclusion * patient agreeing to the collection of data from their cpap/apap device via teletransmission * patient equipped with a device compatible with the resmed telemonitoring data platform * patient who has signed the informed consent form for the study exclusion criteria: * obese patient presenting hypoventilation * patient at risk of other sleep disorders (e.g. severe insomnia) * patient with physical, mental or cognitive inability to use all components of the remote medical monitoring project and individualised treatment plan, as determined by the investigator wishing to include the patient * patient with severe copd (fev1 ≤ 50% predicted or modified medical research council (mmrc) dyspnoea scale \> 2) * patient with severe chronic heart failure (nyha stage iii or iv) * patient's refusal of cpap/apap treatment support * previous cpap/apap treatment for sleep apnoea * patient with ongoing mandibular advancement device (mad) or in the 12 previous months * patient with no permanent place of residence * patient participating in another drug or device study within the previous 30 days

Keywords: cpap/apap vitalcare homecare provider individualised treatment plan
pediatric patients with metabolic or other genetic disorders

Conditions: Genetic Disorder; Asperger Disorder; Autism Spectrum Disorder; Fragile X Syndrome; Developmental Delay

Summary: background: some patients with unusual genetic conditions are referred to the national institutes of health (nih). they may not be eligible to join current research studies. testing such patients is a good way to improve the skills of research staff. the findings could lead to new processes and research. objectives: to recruit a diverse group of pediatric subjects with genetic disorders. to give clinic staff hands-on experience working with these patients. eligibility: children any age with a known or suspected genetic disorder. design: participants will be screened with medical history and physical exam. they may have lab and other tests. family members may give dna samples. participants will have: medical history physical exam height, weight, and other measurements taken. a clinical evaluation of their disorder. they may have: blood, urine, and saliva samples taken imaging tests. these may include x-rays, scans, ultrasound, or skeletal survey. a sleep study a visit with other specialists at nih a genetic test from a commercial lab medical photographs taken other tests participants may have follow-up visits. they may get medical or surgical treatment. ...

the aim of this protocol is to allow genetic-related evaluations for patients with a variety of known or suspected genetic disorders.) if not eligible for a specific nichd research protocol, patients with genetic-related conditions may be evaluated under the auspices of this protocol to provide stimuli for new clinical research initiatives. standard medically-indicated laboratory or radiological studies may be performed to confirm a diagnosis or to aid in the management of the patient. clinical data and excess biospecimens collected as part of clinical care will be analyzed for research purposes. in some cases, the subjects may receive medical or surgical treatment for their disorder at the nih cc according to current clinical practice. the overall purpose of genetic evaluations under this protocol is to support our research missions, generate hypotheses bank specimens for analysis or future use as controls. family members of subjects evaluated on this protocol (who have informative meiotic inheritance relationships to the proband or index case) may also be enrolled.

Eligibility criteria:
* inclusion criteria: * subjects of any age with known or suspected genetic disorder * for relatives of subjects with a genetic disorder: subject is a family member of the proband exclusion criteria: -presence of a medical, psychiatric, or social condition which, in the opinion of the investigator, would place undue burden on the subject, nih resources, or increase risk of participation

Keywords: genetics metabolic dysmorphic syndromes developmental delay genetic counseling natural history
evaluation of immunoregulatory cells in hematopoietic stem cell transplant

Conditions: Hematopoietic Stem Cell Transplantation; Graft vs Host Disease

Summary: the investigators' hypothesis is that the graft-versus-tumor effect can be enhanced while minimizing the complications of graft-versus-host disease.

the investigators' hypothesis is that the graft-versus-tumor effect can be enhanced while minimizing the complications of graft-versus-host disease (gvhd) by determining the qualitative and quantitative changes in t regulatory cells throughout the transplant process. their understanding of this can lead to new treatment strategies and improved clinical therapeutic implications.

Eligibility criteria:
inclusion criteria: * patients 18-70 years old undergoing either autologous transplant or allogeneic transplant for various hematologic conditions exclusion criteria: * patients \ 70 years old undergoing either autologous transplant or allogeneic transplant

Keywords: t-lymphocyte subsets